Previous 10 |
As the post-IPO quiet period ends for Silverback Therapeutics (SBTX), Goldman Sachs weighs in on the stock with a buy recommendation, citing the company’s unique platform targeting the immune system.The price target is $43, implying only ~14.2% upside on today’s close after the ...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Expectations are coming in for 2021. Despite the strong recent gains and record valuations, analysts and investors are expecting even more upside based on "the new normal". The IPO market has proven to be an extremely valuable indicator for future returns. Investors are clearly missin...
Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infec...
News, Short Squeeze, Breakout and More Instantly...
Silverback Therapeutics Inc. Company Name:
SBTX Stock Symbol:
NASDAQ Market:
neffy ® (epinephrine nasal spray) New Drug Application (NDA) and CRL response under review by FDA with anticipated review completion by early October 2024 Response submitted for neffy Marketing Authorization Application (MAA) to EMA’s CHMP; CHMP...
CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat dose PK/PD study of neffy under NAC conditions and updated ...
Response addresses all additional requests in FDA CRL, including positive data from a repeat dose PK/PD study of neffy under nasal allergen challenge (NAC) conditions, and updated testing that detected no measurable nitrosamine levels, conducted per August 2023 FDA Guidance Submission...